Literature DB >> 19146793

ONTARGET: How much RAS inhibition is enough?

Alan B Weder.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19146793     DOI： 10.1007/s11906-009-0002-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  8 in total

1.  Recent clinical trials: the good, the bad, and the misleading.

Authors:  Norman M Kaplan
Journal:  Hypertension       Date:  2008-08-11       Impact factor: 10.190

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors:  Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

4.  Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

Authors:  Norman K Hollenberg; Hans-Henrik Parving; Giancarlo Viberti; Giuseppe Remuzzi; Susan Ritter; Steven Zelenkofske; Albert Kandra; William L Daley; Ricardo Rocha
Journal:  J Hypertens       Date:  2007-09       Impact factor: 4.844

5.  Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.

Authors:  Regina Kunz; Chris Friedrich; Marcel Wolbers; Johannes F E Mann
Journal:  Ann Intern Med       Date:  2007-11-05       Impact factor: 25.391

6.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

7.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

Review 8.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.